Wellinghoff Darryl 4
4 · LA JOLLA PHARMACEUTICAL CO · Filed Feb 4, 2020
Insider Transaction Report
Form 4
Wellinghoff Darryl
Chief Commercial Officer
Transactions
- Award
Common Stock
[F1]2020-01-31$5.82/sh+282$1,641→ 8,015 total - Award
Stock Option (Right to Buy)
[F2]2020-01-31+282→ 282 totalExercise: $6.85Exp: 2030-01-31→ Common Stock (282 underlying)
Footnotes (2)
- [F1]These shares were acquired on 01/31/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.
Signature
/s/ Ryan Murr, as attorney-in-fact for Darryl Wellinghoff|2020-02-04